Abstract
The aim of the study was to evaluate the clinical efficacy of an integrated approach to therapy and prevention of relapse of bacterial vaginosis in women of reproductive age with overweight and obesity. We examined 60 women of reproductive age (19–39 years) with overweight and obesity (BMI+30±4.2) and a verified diagnosis of recurrent bacterial vaginosis (real-time PCR, diagnostic system Femoflor–16). The effectiveness of treatment of bacterial vaginosis in overweight and obese women was 94.0% due to the rapid elimination of the pathogen by a single dose of 2 g of the drug group 5-nitroimidazoles Secnidox and macrolide 16-membered antibiotic with bactericidal mechanism Doramycin (World Medicine, United Kingdom). Combination prolonged therapy with the multi-strain probiotic Brevelac and the natural drug Reitoil increased the remission period of bacterial vaginosis to 6 months in 91.0% of this group of patients. Keywords: bacterial vaginosis, overweight, obesity, therapy, remission.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
